StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The trial's positive outcomes could drive future investor confidence, akin to other biotech firms exiting trials with strong results.
What happened, with direct paths to the underlying reporting
TRVI’s Phase 2b CORAL trial showed significant cough reduction with Haduvio. Top-line results revealed reductions of 60.2%, 53.4%, and 47.9% versus placebo. 65% of patients showed 50% cough reduction using 108 mg BID Haduvio. Statistically significant results were observed in multiple secondary endpoints. Stock declined by 10.45% at $5.83 despite positive data release.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.